1:14 PM ET
8-K
Business Update
OS Therapies Business Update
OS Therapies received a VAT refund of approximately $900,000 from the U.K. tax authority (HMRC) to support the development of its lead product candidate, Herlystic. The company also clarified that the FDA's suspension of the Commissioner’s National Priority Voucher program does not impact the candidate's eligibility for the transferable rare pediatric disease priority review voucher program.
- Counterparty
- HM Revenue and Customs